Althera Pharms Drug Patent Portfolio
Althera Pharms owns 1 orange book drug protected by 2 US patents Given below is the list of Althera Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status | 
|---|---|---|---|
| US10376470 | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases | 01 May, 2033 | Active | 
| US9763885 | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases | 01 May, 2033 | Active | 
Latest Legal Activities on Althera Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Althera Pharms.
| Activity | Date | Patent Number | 
|---|---|---|
|   | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 13 Feb, 2023 | US10376470 | 
| Change in Power of Attorney (May Include Associate POA)  Critical
                   | 08 Oct, 2021 | US9763885 | 
| Email Notification  Critical
                   | 08 Oct, 2021 | US10376470 | 
| Change in Power of Attorney (May Include Associate POA)  Critical
                   | 08 Oct, 2021 | US10376470 | 
| Email Notification  Critical
                   | 08 Oct, 2021 | US9763885 | 
| Correspondence Address Change  Critical
                   | 06 Oct, 2021 | US10376470 | 
| Payment of Maintenance Fee, 4th Yr, Small Entity | 23 Nov, 2020 | US9763885 | 
| Patent Issue Date Used in PTA Calculation  Critical
                   | 13 Aug, 2019 | US10376470 | 
| Recordation of Patent Grant Mailed  Critical
                   | 13 Aug, 2019 | US10376470 | 
| Email Notification  Critical
                   | 25 Jul, 2019 | US10376470 | 
| Issue Notification Mailed  Critical
                   | 24 Jul, 2019 | US10376470 | 
| Dispatch to FDC | 03 Jul, 2019 | US10376470 | 
| Filing Receipt - Corrected | 26 Jun, 2019 | US10376470 | 
| Change in Power of Attorney (May Include Associate POA)  Critical
                   | 26 Jun, 2019 | US10376470 | 
| Email Notification  Critical
                   | 26 Jun, 2019 | US10376470 | 
Althera Pharms's Family Patents
 
 Althera Pharms Drug List
Given below is the complete list of Althera Pharms's drugs and the patents protecting them.
1. Roszet
Roszet is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status | 
|---|---|---|---|
| US10376470 | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases | 01 May, 2033 
                  (7 years from now)
                 | Active | 
| US9763885 | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases | 01 May, 2033 
                  (7 years from now)
                 | Active | 
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Roszet's drug page
